Evogene Valuation
Is EVGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EVGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EVGN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EVGN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EVGN?
Key metric: As EVGN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EVGN's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | US$7.48m |
| Market Cap | US$8.78m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | -0.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EVGN's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.2x | ||
PLNT PlantArc Bio | 1x | n/a | ₪4.9m |
CANF Can-Fite BioPharma | 21.5x | 67.2% | ₪53.1m |
UNVO Univo Pharmaceuticals | 0.06x | n/a | ₪2.8m |
BLRX BioLineRx | 2x | 26.2% | ₪128.4m |
EVGN Evogene | 1.2x | 45.0% | ₪32.5m |
Price-To-Sales vs Peers: EVGN is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (8.2x).
Price to Sales Ratio vs Industry
How does EVGN's PS Ratio compare vs other companies in the Asian Biotechs Industry?
Price-To-Sales vs Industry: EVGN is good value based on its Price-To-Sales Ratio (1.2x) compared to the Asian Biotechs industry average (9.4x).
Price to Sales Ratio vs Fair Ratio
What is EVGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 2.9x |
Price-To-Sales vs Fair Ratio: EVGN is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.